Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tourmaline Bio, Inc. - Common Stock (NQ: TRML ) 28.76 +1.10 (+3.98%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 238,069 Open 27.37 Bid (Size) 28.14 (3) Ask (Size) 29.15 (1) Prev. Close 27.66 Today's Range 26.39 - 29.55 52wk Range 12.12 - 48.31 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 07, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio to Present at Upcoming Investor Conferences October 31, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Performance YTD +8.53% +8.53% 1 Month +5.81% +5.81% 3 Month +105.87% +105.87% 6 Month +98.34% +98.34% 1 Year +77.64% +77.64% More News Read More Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 October 15, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023 March 19, 2024 Via InvestorPlace Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress October 11, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board October 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio to Present at Upcoming Investor Conferences September 03, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024 August 08, 2024 Via InvestorPlace Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 August 02, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer June 27, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio to Present at the Jefferies Global Healthcare Conference May 23, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial May 16, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024 May 13, 2024 Via InvestorPlace Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights May 13, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Avalo Therapeutics Appoints Biotech Leaders to Board of Directors April 02, 2024 From Avalo Therapeutics Via GlobeNewswire Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session March 21, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session March 21, 2024 Via Benzinga Dow Jumps 200 Points; US Weekly Jobless Claims Fall March 21, 2024 Via Benzinga Topics Stocks Exposures US Equities Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results March 21, 2024 Via Investor's Business Daily 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 21, 2024 Via Benzinga Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session March 21, 2024 Via Benzinga Topics Stocks Exposures US Equities Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights March 19, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares January 29, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Pricing of Public Offering of Common Stock January 25, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
